TScan Therapeutics (TCRX) Competitors $2.97 -0.04 (-1.33%) (As of 12/17/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends TCRX vs. ALT, EXAI, TERN, ORIC, VECT, TRML, PHAT, HUMA, ATXS, and DNAShould you be buying TScan Therapeutics stock or one of its competitors? The main competitors of TScan Therapeutics include Altimmune (ALT), Exscientia (EXAI), Terns Pharmaceuticals (TERN), ORIC Pharmaceuticals (ORIC), VectivBio (VECT), Tourmaline Bio (TRML), Phathom Pharmaceuticals (PHAT), Humacyte (HUMA), Astria Therapeutics (ATXS), and Ginkgo Bioworks (DNA). These companies are all part of the "pharmaceutical products" industry. TScan Therapeutics vs. Altimmune Exscientia Terns Pharmaceuticals ORIC Pharmaceuticals VectivBio Tourmaline Bio Phathom Pharmaceuticals Humacyte Astria Therapeutics Ginkgo Bioworks TScan Therapeutics (NASDAQ:TCRX) and Altimmune (NASDAQ:ALT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, media sentiment, valuation, profitability, dividends, community ranking and institutional ownership. Do analysts prefer TCRX or ALT? TScan Therapeutics presently has a consensus price target of $11.25, indicating a potential upside of 278.79%. Altimmune has a consensus price target of $20.00, indicating a potential upside of 138.10%. Given TScan Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe TScan Therapeutics is more favorable than Altimmune.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TScan Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Altimmune 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.88 Which has more risk and volatility, TCRX or ALT? TScan Therapeutics has a beta of 0.79, indicating that its stock price is 21% less volatile than the S&P 500. Comparatively, Altimmune has a beta of 0.15, indicating that its stock price is 85% less volatile than the S&P 500. Is TCRX or ALT more profitable? TScan Therapeutics has a net margin of -1,188.88% compared to Altimmune's net margin of -199,076.92%. Altimmune's return on equity of -55.81% beat TScan Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets TScan Therapeutics-1,188.88% -58.72% -36.02% Altimmune -199,076.92%-55.81%-50.60% Does the media refer more to TCRX or ALT? In the previous week, TScan Therapeutics had 7 more articles in the media than Altimmune. MarketBeat recorded 14 mentions for TScan Therapeutics and 7 mentions for Altimmune. Altimmune's average media sentiment score of 0.59 beat TScan Therapeutics' score of 0.30 indicating that Altimmune is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TScan Therapeutics 2 Very Positive mention(s) 5 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Altimmune 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Which has preferable valuation and earnings, TCRX or ALT? Altimmune has lower revenue, but higher earnings than TScan Therapeutics. Altimmune is trading at a lower price-to-earnings ratio than TScan Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTScan Therapeutics$21.05M7.53-$89.22M-$1.06-2.80Altimmune$52K11,489.42-$88.45M-$1.55-5.42 Do institutionals & insiders have more ownership in TCRX or ALT? 82.8% of TScan Therapeutics shares are held by institutional investors. Comparatively, 78.1% of Altimmune shares are held by institutional investors. 2.8% of TScan Therapeutics shares are held by insiders. Comparatively, 4.1% of Altimmune shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the MarketBeat Community believe in TCRX or ALT? Altimmune received 22 more outperform votes than TScan Therapeutics when rated by MarketBeat users. However, 80.95% of users gave TScan Therapeutics an outperform vote while only 72.73% of users gave Altimmune an outperform vote. CompanyUnderperformOutperformTScan TherapeuticsOutperform Votes3480.95% Underperform Votes819.05%AltimmuneOutperform Votes5672.73% Underperform Votes2127.27% SummaryTScan Therapeutics beats Altimmune on 11 of the 19 factors compared between the two stocks. Ad Brownstone ResearchDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but designed to power a $9 trillion AI revolution. And I’ve identified a little-known supplier Elon is depending on to make it all happen.I urge you to watch this video now. Get TScan Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TCRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TCRX vs. The Competition Export to ExcelMetricTScan TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$158.51M$2.98B$5.14B$9.31BDividend YieldN/A1.85%4.81%4.06%P/E Ratio-2.8046.24135.1817.54Price / Sales7.53440.311,228.03140.34Price / CashN/A182.1340.6537.95Price / Book0.943.924.884.92Net Income-$89.22M-$42.03M$118.97M$225.78M7 Day Performance-3.57%-3.37%15.73%-1.58%1 Month Performance-29.29%7.95%15.69%6.67%1 Year Performance-35.57%21.00%34.73%22.48% TScan Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TCRXTScan Therapeutics2.796 of 5 stars$2.97-1.3%$11.25+278.8%-40.0%$158.51M$21.05M-2.80100ALTAltimmune2.1771 of 5 stars$8.98-0.6%$20.00+122.7%+9.5%$638.70M$52,000.00-5.8350Positive NewsEXAIExscientia1.2867 of 5 stars$4.84+3.2%$7.00+44.6%-17.5%$632.93M$25.60M-3.21280High Trading VolumeTERNTerns Pharmaceuticals4.2461 of 5 stars$6.98+3.7%$18.30+162.2%+7.1%$592.88M$1M-5.7040ORICORIC Pharmaceuticals3.7727 of 5 stars$8.24-3.3%$18.29+121.9%-11.4%$581.50MN/A-4.6880Insider TradeNews CoveragePositive NewsGap DownVECTVectivBioN/A$16.85flatN/AN/A$573.24M$27.34M0.0030TRMLTourmaline Bio2.1359 of 5 stars$21.90+0.4%$54.00+146.6%+9.3%$561.58MN/A-7.7344PHATPhathom Pharmaceuticals2.9256 of 5 stars$8.14+3.2%$23.00+182.6%-4.0%$556.61M$680,000.00-1.48110Gap UpHUMAHumacyte3.5622 of 5 stars$4.34+5.9%$13.00+199.5%+22.8%$546.23M$1.57M-3.06150Short Interest ↑ATXSAstria Therapeutics1.8473 of 5 stars$9.64+1.3%$25.60+165.6%+52.8%$543.99MN/A-4.5630Short Interest ↑DNAGinkgo Bioworks0.7441 of 5 stars$9.43-0.1%$4.58-51.5%N/A$542.04M$251.46M-0.721,218News CoveragePositive News Related Companies and Tools Related Companies Altimmune Competitors Exscientia Competitors Terns Pharmaceuticals Competitors ORIC Pharmaceuticals Competitors VectivBio Competitors Tourmaline Bio Competitors Phathom Pharmaceuticals Competitors Humacyte Competitors Astria Therapeutics Competitors Ginkgo Bioworks Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:TCRX) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TScan Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TScan Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
